Lumos Diagnostics Accelerates FebriDx Expansion with 30-Site Rollout in Leading U.S. Urgent Care Network

Leading Health System Operator Advances Multi-Site FebriDx Deployment

Lumos Diagnostics has reached a critical milestone with a leading regional urgent care group operated by a major U.S. health system moving directly into network rollout. This health system operator will implement FebriDx across its entire urgent care network, consisting of over 30 sites. Internal estimates indicate this deployment will address roughly 200,000 acute respiratory infection presentations annually across these locations. The health system operates more than 200 facilities in a major U.S. metropolitan area, including urgent care centers, hospitals, ambulatory clinics, and medical group practices.

The rapid progression from initial discussions to deployment illustrates increasing clinical confidence in FebriDx as an effective diagnostic tool. FebriDx is anticipated to enhance acute respiratory infection triage protocols, support antibiotic stewardship programs, and standardize workflows across urgent care and related ambulatory settings within the network. This announcement aligns with Lumos' strategic emphasis on health system-affiliated urgent care groups, noting that approximately 58 of the top 100 urgent care groups are owned or affiliated with major U.S. health systems. This channel offers a vital pathway for Lumos to scale FebriDx adoption across interconnected healthcare facilities.

Structured Four-Stage Commercial Framework Guides Account Advancement

Lumos has implemented a four-stage commercial framework to monitor and communicate the progress of priority accounts toward FebriDx adoption. This framework provides transparency for investors on the maturity journey from initial engagement to full integration within clinical workflows. The stages include qualified opportunities, which identify priority accounts based on patient volume, payer mix, strategic alignment, and network size. Clinical and economic validation involves targeted assessments at multiple sites to evaluate clinical performance, reimbursement, workflow integration, and health-economic outcomes that support broader adoption decisions.

The network rollout phase involves deploying FebriDx across multiple sites within an account following successful validation of clinical utility, operational compatibility, and reimbursement readiness. The final stage, standardized adoption, is achieved when FebriDx is embedded into standing orders, triage protocols, or routine clinical pathways, enabling repeat ordering and scaled utilization across the account. This framework mirrors the progression seen with Lumos' existing client WellStreet Urgent Care, where an initial pilot expanded to 44 sites and paved the way for nationwide deployment across WellStreet's network of more than 165 sites. This structured approach allows Lumos to effectively communicate account maturity to investors while tracking advancement toward large-scale adoption within health systems.

Three Tier-One Urgent Care Networks Undergoing Clinical Validation

In addition to the regional health system entering network rollout, Lumos is progressing clinical and economic validation with three other tier-one urgent care groups from its top 100 target list. These include a top 10, top 25, and top 30 organization, collectively representing over 230 urgent care sites. The validation phase involves comprehensive assessments across multiple locations to measure FebriDx's clinical performance, reimbursement pathways, workflow integration, and health-economic impact. Successful validation typically accelerates expansion within each account, as demonstrated by the WellStreet case.

Together with the regional health system deploying FebriDx at 30 sites, these four priority accounts encompass more than 430 potential sites and an estimated 2.6 million acute respiratory infection presentations annually. This scale underscores the significant clinical opportunity within Lumos' top 100 target strategy, which covers an estimated 40 percent of total U.S. urgent care sites. Lumos continues to engage additional high-volume accounts within this target list, positioning itself to capitalize on substantial opportunities within the fragmented urgent care market.

Exclusive U.S. Distribution Partnership with Phase Scientific Drives Market Access

All U.S. sales of FebriDx are facilitated through Lumos' exclusive distribution agreement with Phase Scientific, disclosed to the ASX on 16 July 2025. Lumos recognizes revenue upon shipment of product to Phase Scientific, establishing a clear revenue recognition point in the supply chain. This distribution model enables Lumos to concentrate on clinical validation, commercial strategy, and product development, while Phase Scientific manages logistics and market distribution across the U.S. urgent care sector.

The exclusive partnership provides Lumos with a scalable pathway to expand FebriDx adoption across multiple urgent care networks without building a direct sales and logistics infrastructure nationwide. As validation progresses and network rollouts increase, demand for FebriDx products distributed via Phase Scientific is expected to grow proportionally. This model has facilitated rapid account wins with WellStreet Urgent Care and the regional health system operator, validating the effectiveness of the distribution partnership in supporting Lumos' commercialization efforts.

Strategic Targeting of Top 100 Urgent Care Groups Captures 40 Percent of U.S. Market

Lumos' commercial strategy focuses on the top 100 urgent care groups, which represent approximately 40 percent of all U.S. urgent care sites. This targeted approach allows efficient allocation of resources toward large-scale accounts with multi-site networks and centralized decision-making, enabling faster adoption post-clinical validation. Market insights reveal that about 58 of these top 100 groups are owned or affiliated with large health systems, providing Lumos with strategically significant accounts for network deployments.

By prioritizing these high-volume accounts, Lumos aims to establish anchor deployments that demonstrate FebriDx's clinical utility and operational compatibility within integrated healthcare networks. Success in these accounts can drive expansion into broader health system networks, including ambulatory clinics, emergency departments, and related care settings. This strategy contrasts with targeting smaller, independent urgent care practices individually, instead leveraging the coordinated decision-making and inter-site collaboration of large health systems to accelerate adoption.

FebriDx Enhances Acute Respiratory Infection Triage and Antibiotic Stewardship

FebriDx supports acute respiratory infection triage protocols and antibiotic stewardship initiatives in urgent care and ambulatory settings. The test aids healthcare providers in accurately diagnosing and managing acute respiratory infections, potentially reducing unnecessary antibiotic use and promoting appropriate treatment decisions. The regional health system operator and three tier-one accounts currently validating FebriDx are assessing its integration into clinical workflows and cost-effective patient management strategies.

The estimated 2.6 million acute respiratory infection presentations annually across these four priority accounts represent the clinical opportunity driving Lumos' commercialization. Influenza testing prevalence in urgent care serves as a benchmark for estimating FebriDx demand once accounts reach standardized adoption. As health systems incorporate FebriDx into standing orders and routine triage protocols, the test becomes embedded in clinical pathways, supporting repeat ordering and scaled utilization.

Diversified Point-of-Care Diagnostic Platform Supports Multiple Conditions

Lumos Diagnostics specializes in rapid, comprehensive point-of-care diagnostic technologies that assist healthcare professionals in diagnosing and managing medical conditions. The company operates across several segments, including customized assay development, manufacturing services for point-of-care tests, and proprietary digital reader platforms. Beyond FebriDx commercialization, Lumos develops, manufactures, and markets proprietary Lumos-branded point-of-care tests targeting infectious and inflammatory diseases. This diversified model enables Lumos to serve both third-party partners requiring diagnostic solutions and direct market channels for its own branded tests.

FebriDx is a core asset within Lumos' proprietary portfolio, focusing on rapid diagnosis of acute respiratory infections. The platform supports deployment in time-sensitive clinical settings such as urgent care centers, where immediate diagnostic information is critical for triage and treatment decisions. Lumos is headquartered in Melbourne, Victoria, Australia, serving as a hub for research, development, and manufacturing activities that underpin global product commercialization. The expanding adoption of FebriDx across U.S. urgent care networks validates the commercial potential of Lumos' diagnostic technology within the infectious disease testing market.

Consistent Market Communication with Enhanced Account-Level Transparency

Lumos has emphasized that this update supplements previously disclosed commercial metrics by providing detailed account-level insights without replacing existing reporting frameworks. The company will maintain reporting consistency aligned with its June 11, 2026 market framework, including site growth, geographic expansion, and influenza testing benchmarks for acute respiratory infection opportunities. This approach ensures investors can track commercialization progress against established guidelines.

Concurrently, Lumos plans to refine communication of account maturity by incorporating its four-stage commercial progression framework: qualified opportunities, clinical and economic validation, network rollout, and standardized adoption. This dual reporting strategy offers investors both high-level progress metrics and granular account-specific updates, illustrating how priority accounts evolve over time. As more accounts advance toward network rollout and standardized adoption, Lumos' reporting will showcase expanding commercial traction for FebriDx across multiple priority health systems and urgent care networks.

Investment Milestone and Forward Outlook

The expansion of FebriDx across multiple priority accounts marks a pivotal point in Lumos' U.S. commercialization strategy. The immediate network rollout commitment from a leading regional health system operator confirms clinical acceptance and reimbursement readiness within a major health system. The progression of three tier-one accounts through clinical and economic validation reflects growing interest from the largest U.S. urgent care organizations, with validation underway at multiple sites within each account. These developments signal building momentum in Lumos' top 100 account targeting approach.

Investors should monitor the pace at which the three tier-one accounts complete validation and transition to network rollout. The scale and timing of expansion within the regional health system's 30-site deployment will also be critical, as successful execution could accelerate engagement with additional top 100 accounts currently in the qualified opportunities phase. Lumos' June 2026 investor presentation outlined its overall commercialization strategy; these latest updates provide concrete examples of accounts advancing along the strategic pathway detailed previously.